Clinical Outcomes of Melatonin Supplementation As Adjuvant Therapy of In-Vitro Fertilization

Clinical Outcomes of Melatonin Supplementation as Adjuvant Therapy: A Randomized Controlled Trial Amongst Women Undergoing In-Vitro Fertilization at Jos University Teaching Hospital, Plateau State, North-Central, Nigeria

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202308477172970

Enrollment

Registered

2023-08-11

Start date

2023-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female

Interventions

Melatonin supplementation

placebo group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: • Aged 18 years to 52 years • Currently diagnosed infertile (unable to achieve conception after 1 year of regular unprotected intercourse) in the Jos University Teaching Hospital Gynecology Clinic • Have been scheduled to undergo conventional in-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)

Exclusion criteria

Exclusion criteria: • On drugs (such as antidepressants) or supplements that could affect serum melatonin levels • With medical conditions that may alter serum melatonin profile such as; Cushing’s Disease, Klinefelter Syndrome, Turner Syndrome, Coronary Heart Disease, Schizophrenia, Alzheimer’s Disease Psoriasis Vulgaris, Myelomeningocele, Sarcoidosis, Anorexia Nervosa, Bulimia Nervosa and others. • Active Smokers • Those who have a history of alcohol misuse in the preceding three months • Those who are concurrently using other adjuvant therapies (e.g., Chinese herbs) • Patients scheduled to undergo conventional in-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) but recommended to use or opted for donor eggs.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure for this study will be the rate of fertilization and clinical pregnancy between the treatment and control groups.;The primary outcome measure for this study will be the rate of fertilization and clinical pregnancy between the treatment and control groups. This will be done between participants who will be on cycles of either Conventional Invitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI).	—

Measure

Time frame

The primary outcome measure for this study will be the rate of fertilization and clinical pregnancy between the treatment and control groups.;The primary outcome measure for this study will be the rate of fertilization and clinical pregnancy between the treatment and control groups. This will be done between participants who will be on cycles of either Conventional Invitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI).

—

Secondary

Measure	Time frame
conventional IVF or ICSI	—

Countries

Nigeria

Contacts

Public ContactChinedu Ekwempu

MD Kauna Specialist Hosptal Jos

cekwempu@yahoo.co.uk+2348033173362

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026